Named Patient Program for Mitomycin for Pyelocalyceal Solution
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2022
CompletedFirst Posted
Study publicly available on registry
August 10, 2022
CompletedFebruary 28, 2025
February 1, 2025
August 5, 2022
February 25, 2025
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients who are suitable to receive JELMYTO and for whom there is reasonable expectation that JELMYTO may provide clinical benefit based on the medical judgment of their prescribing physician.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UroGen Pharma Ltd.lead
- Tanner Pharma Groupcollaborator
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 5, 2022
First Posted
August 10, 2022
Last Updated
February 28, 2025
Record last verified: 2025-02